Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity (RVTY) Valuation Check After Recent Share Price Rebound And Margins Reset Narrative

2026-01-29
Event context and recent price moves Revvity (RVTY) recently caught investor attention after a period where the share price shows a return of about 14% over the past month and roughly 22% over the past 3 months, despite a negative 1 year total return. See our latest analysis for Revvity. At a share price of $111.13, Revvity is coming off a sharp 30 day share price return of about 14% and a 90 day gain of roughly 22%. However, the 1 year total shareholder return is still close to 10% lower and...

Will Revvity Q4 Earnings Benefit From Early Signs of Demand Recovery?

2026-01-29
RVTY's Q4 results are likely to benefit from early demand recovery signs in Life Sciences, but China Diagnostics headwinds may limit earnings upside.

Curious about Revvity (RVTY) Q4 Performance? Explore Wall Street Estimates for Key Metrics

2026-01-28
Besides Wall Street's top-and-bottom-line estimates for Revvity (RVTY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

Elevance Health (ELV) Beats Q4 Earnings Estimates

2026-01-28
Elevance Health (ELV) delivered earnings and revenue surprises of +7.30% and -0.45%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Revvity Board Declares Quarterly Dividend

2026-01-26
WALTHAM, Mass., January 26, 2026--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026.

Revvity (RVTY) Earnings Expected to Grow: Should You Buy?

2026-01-26
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?

2026-01-23
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

2026-01-21
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector.

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

2026-01-21
Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.

The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance

2026-01-14
In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...